The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation

Journal of Arrhythmia

Volumn 29, Issue 3, 2013, Pages 190-200

  Ogawa, Satoshi ^a   Aonuma, Kazutaka ^b   Tse, Hung Fat ^c   Huang, Dejia ^d   Huang, Jin Long ^e   Kalman, Jonathan ^f   Kamakura, Shiro ^g   Nair, Mohan ^h   Shin, Dong Gu ⁱ   Stiles, Martin ^j   Teo, Wee Siong ^k   Yamane, Teiichi ^l  

^a International University of Health and Welfare Mita Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d SICHUAN UNIVERSITY   (China)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^h Max Heart and Vascular Institute   (India)

ⁱ Young Nam University Hospital   (South Korea)

^j WAIKATO HOSPITAL   (New Zealand)

^k DEPARTMENT OF CARDIOLOGY   (Singapore)

^l JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882453013     PISSN: 18804276     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joa.2013.03.002     Document Type: Article

References (43)

1. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39: 1901-19.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee of practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114: e257-354.
3. You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141: e531S-75.
4. European Heart Rhythm Association. European Association for cardio-thoracic surgery: guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369-429.
5. Camm AJ, Lip GYH, Caterina RD, et al. Focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012;33: 2719-47, http://dx. doi.org/10.1093/eurheartj/ehs253.
6. Department of Health, Western Australia. Quick reference guide: atrial fibrillation information for the health practitioner. Perth: Health Networks Branch. Department of Health, Western Australia; 2011.
7. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27: 74-90.
8. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28: 125-36.
9. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS2008): digest version. Circ J 2010;74: 2479-500.
10. Ogawa S, Aonuma K, Huang D, et al. Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-Pacific region. J Arrhythmia 2012;28: 41-55.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363: 1875-918.
13. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365: 883-91.
14. Granger CB, Alexander JH, McMurrayJJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-92.
15. Ogawa S, Hori M. Urgent statement on antithrombotic therapy of atrial fibrillation. Circ J 2011;75: 2719-21.
16. Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012;141: 147-53.
17. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with AF. A report from the Swedish AF Cohort study. Circulation 2012;125: 2298-307.
18. Banerjee A, Lane DA, Torp-Pederson C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107: 584-9.
19. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123: 2363-72.
20. Halperin JL, Wojdyla D, Piccini JP, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF Trial [abstract]. Stroke 2012;43: A148.
21. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151: 297-305.
22. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006;37: 447-51. (Pubitemid 43732003)
23. Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. JACC 2007;50: 309-15. (Pubitemid 47061504)
24. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106: 739-49.
25. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999;131: 927-34. (Pubitemid 30005032)
26. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27: 3018-26. (Pubitemid 44963431)
27. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. JACC 2005;46: 1729-36. (Pubitemid 41531631)
28. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulation in atrial fibrillation: a systematic review. Am J Med 2010;123(638-45): e4.
29. Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost 2011;9: 441-9.
30. Garcia DA, Granger CB. Anticoagulation, novel agents, and procedures. Can we pardon the interruption? Circulation 2012;126: 255-7.
31. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin. Results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126: 343-8.
32. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610-6. (Pubitemid 28371183)
33. Yasaka M, Naritomi H, Minematsu K, et al. Ischemic stroke associated with brief cessation of warfarin. Thromb Res 2006;118: 290-3. (Pubitemid 43816675)
34. Evans IL, Sayers MS, Gibbons AJ, et al. Can warfarin be continued during dental extraction? Result of a randomized controlled trial Br J Oral Maxillofac Surg 2002;40: 248-52. (Pubitemid 34760054)
35. Ardekian L, Gaspar R, Peled M, et al. Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000;131: 331-5.
36. Dang M-TN, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39: 1008-12. (Pubitemid 40695964)
37. Yu HC, Chan TY, Critchley JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJ Med 1996;89: 127-35. (Pubitemid 26053126)
38. You JH, Chan FW, Wong RS, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005;59: 582-7. (Pubitemid 40632249)
39. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001;40: 1183-8. (Pubitemid 34110494)
40. Hori M, Connolly SJ, Zhu J, et al. Efficacy and safety of dabigatran versus warfarin in patients with atrial fibrillation: analysis in Asian population in RELY trial. Cerebrovasc Dis 2012;34(Suppl 1): S6-4.
41. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376: 975-83.
42. Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57: 1330-7.
43. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123: 131-6.